Exclusive: BioNTech acquires lipid nanoparticle startup founded by George Mason and UPenn scientists
BioNTech, the German drug company famous for developing a Covid-19 vaccine with Pfizer, has acquired AexeRNA and its novel lipid nanoparticles for mRNA medicines, Endpoints News has learned.
AexeRNA is a tiny startup that largely exists on paper. It has no lab or staff scientists, just a former patent lawyer as its CEO and several scientific co-founders, including mRNA pioneer and recent Nobel Prize laureate Drew Weissman from the University of Pennsylvania, and bioengineer Michael Buschmann of George Mason University.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.